Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment
Phase of Trial: Phase III
Latest Information Update: 18 Sep 2017
At a glance
- Drugs Molindone (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Adverse reactions
- Acronyms CHIME 4
- Sponsors Supernus Pharmaceuticals
- 18 Sep 2017 According to Supernus media release, enrollment in the study continues to be very encouraging at a high level of 90%.
- 13 Jun 2016 Status changed from not yet recruiting to recruiting.
- 02 Mar 2016 According to Supernus media release, company has finalized the special protocol assessment (SPA) with the FDA for this trial and data from this trial is expected by mid-2017.